Rhodium nanoparticles, derived from mesitylene-solvated rhodium atoms, deposited on g-Al2O3, are excellent catalysts for the selective hydrogenation of the double bond in a,b-unsaturated carbonyl compounds. The low metal loading Rh on g-Al2O3 catalyst, containing trioctylamine, TOA, as stabilizing agent of the metal nanoparticles, Rh(TOA)/g-Al2O3, 0.1 wt.% Rh, showed the highest catalytic activity. Using this catalyst 4-(6,-methoxy-2,-naphthyl)-3-buten-2-one was reduced to the anti-inflammatory drug 4-(6,-methoxy-2,-naphthyl)-butan-2-one, NabumetoneTM, with complete selectivity and under mild reaction conditions (room temperature, atmospheric pressure of hydrogen). Similarly, 2-acetyl-5,8-dimethoxy-3,4-dihydronaphthalene was hydrogenated with high selectivity (85%) to 2-acetyl-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalene, precursor of antitumor anthracyclinic compounds, which was obtained chemically pure by crystallization. No leaching of rhodium was observed. The catalyst was completely recovered and, if reused, it works without loss of activity. 1H NMR DOSY analysis of the Rh(TOA)/mesitylene solution evidenced the presence of nanoparticles with a diameter of about 1.1 nm.

Supported rhodium nanoparticles obtained by Metal Vapour Synthesis as catalysts in the preparation of valuable organic compounds

BALZANO, FEDERICA;UCCELLO BARRETTA, GLORIA;SALVADORI, PIERO
2008-01-01

Abstract

Rhodium nanoparticles, derived from mesitylene-solvated rhodium atoms, deposited on g-Al2O3, are excellent catalysts for the selective hydrogenation of the double bond in a,b-unsaturated carbonyl compounds. The low metal loading Rh on g-Al2O3 catalyst, containing trioctylamine, TOA, as stabilizing agent of the metal nanoparticles, Rh(TOA)/g-Al2O3, 0.1 wt.% Rh, showed the highest catalytic activity. Using this catalyst 4-(6,-methoxy-2,-naphthyl)-3-buten-2-one was reduced to the anti-inflammatory drug 4-(6,-methoxy-2,-naphthyl)-butan-2-one, NabumetoneTM, with complete selectivity and under mild reaction conditions (room temperature, atmospheric pressure of hydrogen). Similarly, 2-acetyl-5,8-dimethoxy-3,4-dihydronaphthalene was hydrogenated with high selectivity (85%) to 2-acetyl-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalene, precursor of antitumor anthracyclinic compounds, which was obtained chemically pure by crystallization. No leaching of rhodium was observed. The catalyst was completely recovered and, if reused, it works without loss of activity. 1H NMR DOSY analysis of the Rh(TOA)/mesitylene solution evidenced the presence of nanoparticles with a diameter of about 1.1 nm.
2008
Evangelisti, C.; Panziera, N.; Vitelli, M.; Pertici, P.; Balzano, Federica; UCCELLO BARRETTA, Gloria; Salvadori, Piero
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/196839
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 6
social impact